Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Glucose Transporters01:27

Glucose Transporters

22.3K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

114
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

167
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
167
Secondary Active Transport01:32

Secondary Active Transport

6.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

130
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
130

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

<i>In vitro</i> and <i>in vivo</i> evaluation of DNA-integrated diclofenac-HPMC hydrogel for enhanced ocular anti-inflammatory drug delivery.

Journal of biomaterials science. Polymer edition·2026
Same author

The skin microbiome-immune-barrier axis: implications for inflammatory skin disorders and immunotherapeutic strategies.

Immunotherapy·2026
Same author

Development of HPMC-modified starch/ZnO nanocomposite films using biodegradable plasticizers for improved antioxidant, antimicrobial, and cytocompatible characteristics.

Journal of biomaterials science. Polymer edition·2026
Same author

Correction: Hepatoprotective Mechanism of Shorea Robusta Gaertn. f. Against Isoniazid-induced Hepatotoxicity by Targeting TNF-α, TGF-β1, and PPAR-α: Insights from Computational Profiling To Immunohistochemical Confirmation.

Cell biochemistry and biophysics·2026
Same author

Hepatoprotective Mechanism of Shorea Robusta Gaertn. f. Against Isoniazid-induced Hepatotoxicity by Targeting TNF-α, TGF-β1, and PPAR-α: Insights from Computational Profiling To Immunohistochemical Confirmation.

Cell biochemistry and biophysics·2026
Same author

Metallo-herb complexes as emerging therapeutics: chemistry, synthesis approaches, and pharmacological insights.

Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine·2026

相关实验视频

Updated: May 17, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.5K

对-葡萄糖辅运输体2抑制剂的洞察性观点:导航安全更新和超越.

Pratikeswar Panda1, Rajaram Mohapatra1, Biswajit Samantaray1

  • 1Department of Pharmaceutics, School of Pharmaceutical Science, Siksha 'O' Anusandhan University, Bhubaneswar, Odisha, India.

Current drug research reviews
|April 4, 2025
PubMed
概括

-葡萄糖辅运输体2 (SGLT2) 抑制剂是有效的2型糖尿病治疗方法,具有心血管和脏的好处. 虽然通常是安全的,但潜在的风险,如低血糖和感染,需要仔细监测患者.

关键词:
SGLT2 抑制剂的使用.糖尿病酸性酸性糖尿病骨折,骨折,骨折,骨折,骨折,骨折,骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.骨折.低血糖症 低血糖症下肢截肢是指下肢的截肢.2 型糖尿病 2 型糖尿病尿路感染 尿路感染

更多相关视频

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.7K
Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

5.0K

相关实验视频

Last Updated: May 17, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.5K
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.7K
Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

5.0K

科学领域:

  • 内分泌学 在内分泌学.
  • 腎臟病學 (nephrology) 是一種醫學.
  • 心脏病学 心脏病学

背景情况:

  • -葡萄糖辅运输体2 (SGLT2) 抑制剂代表了用于2型糖尿病管理的新型口服药物类别.
  • 这些 Gliflozin 向SGLT2 在附近的管中,减少葡萄糖和的再吸收,并促进尿中的糖分泌.
  • 除了血糖控制之外,SGLT2抑制剂表现出对心脏和功能有益的类作用.

研究的目的:

  • 提供目前可用的SGLT2抑制剂的全面安全概述.
  • 总结一下与这种类型糖尿病药物相关的已知风险和益处.

主要方法:

  • 对SGLT2抑制剂的安全数据的文献综述.
  • 分析报告的不良事件和临床试验结果.

主要成果:

  • SGLT2 抑制剂显示出显著的心血管和脏保护作用.
  • 潜在的不良事件包括低血糖症,尿路感染,糖尿病酸性脂肪酸症,下肢截肢和骨折.
  • 虽然有些风险并不常见,但它们可能会产生严重的后果,需要密切监督患者.

结论:

  • SGLT2抑制剂是2型糖尿病的有效治疗方法,提供了相当大的心血管和脏保护.
  • 整体安全性概况有利,但对特定不良事件的仔细监测对于患者安全至关重要.